[go: up one dir, main page]

IN2015KN00449A - - Google Patents

Info

Publication number
IN2015KN00449A
IN2015KN00449A IN449KON2015A IN2015KN00449A IN 2015KN00449 A IN2015KN00449 A IN 2015KN00449A IN 449KON2015 A IN449KON2015 A IN 449KON2015A IN 2015KN00449 A IN2015KN00449 A IN 2015KN00449A
Authority
IN
India
Prior art keywords
patient
debrafenib
trametinib
rfs
time period
Prior art date
Application number
Inventor
Sylvie Laquerre
Peter F Lebowitz
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015KN00449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IN2015KN00449A publication Critical patent/IN2015KN00449A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of debrafenib and trametinib for a time period sufficient to increase relapse free survival (RFS).
IN449KON2015 2012-09-04 2013-08-30 IN2015KN00449A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696375P 2012-09-04 2012-09-04
PCT/US2013/057432 WO2014039375A1 (en) 2012-09-04 2013-08-30 Method of adjuvant cancer treatment

Publications (1)

Publication Number Publication Date
IN2015KN00449A true IN2015KN00449A (en) 2015-07-17

Family

ID=50237545

Family Applications (1)

Application Number Title Priority Date Filing Date
IN449KON2015 IN2015KN00449A (en) 2012-09-04 2013-08-30

Country Status (20)

Country Link
US (6) US20150216868A1 (en)
EP (2) EP3981408A1 (en)
JP (3) JP2015527374A (en)
KR (1) KR102134585B1 (en)
CN (2) CN107308164A (en)
AU (2) AU2013313050A1 (en)
BR (1) BR112015004578A2 (en)
CA (1) CA2882437C (en)
CY (1) CY1124812T1 (en)
DK (1) DK2892535T3 (en)
ES (1) ES2900825T3 (en)
HR (1) HRP20211817T1 (en)
HU (1) HUE056646T2 (en)
IN (1) IN2015KN00449A (en)
LT (1) LT2892535T (en)
PL (1) PL2892535T3 (en)
PT (1) PT2892535T (en)
RU (1) RU2640180C2 (en)
SI (1) SI2892535T1 (en)
WO (1) WO2014039375A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039375A1 (en) 2012-09-04 2014-03-13 Glaxosmithkline Llc Method of adjuvant cancer treatment
SG10201804519RA (en) 2013-12-28 2018-07-30 Guardant Health Inc Methods and systems for detecting genetic variants
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
DK3618875T3 (en) 2017-05-02 2023-07-10 Novartis Ag COMBINATION THERAPY INCLUDING A RAF INHIBITOR AND TRAMETINIB
WO2019204399A1 (en) * 2018-04-17 2019-10-24 The University Of Chicago Methods and compositions for treating cancer
CN109106893B (en) * 2018-11-12 2021-04-20 上海市中西医结合医院 Traditional Chinese medicine compound preparation for regulating intestinal barrier function and preparation method thereof
KR102881316B1 (en) 2019-05-13 2025-11-05 노파르티스 아게 A novel crystalline form of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2 (trifluoromethyl)isonicotinamide as a RAF inhibitor for cancer therapy.
WO2021118924A2 (en) * 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50569B (en) * 2004-06-11 2010-05-07 Japan Tobacco Inc. 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PIRIDO (2,3-D) PYRIMIDINE DERIVATIVES AND SIMILAR CANCER UNITS
SI2301531T1 (en) * 2005-02-18 2018-11-30 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PL3560498T3 (en) * 2009-10-16 2022-12-12 Novartis Ag COMBINATION CONTAINING MEK INHIBITOR AND B-RAF INHIBITOR
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
WO2014039375A1 (en) 2012-09-04 2014-03-13 Glaxosmithkline Llc Method of adjuvant cancer treatment

Also Published As

Publication number Publication date
AU2016244279B2 (en) 2018-01-04
KR102134585B1 (en) 2020-07-17
AU2016244279A1 (en) 2016-11-03
AU2013313050A1 (en) 2015-03-26
CN104582706A (en) 2015-04-29
US20210060021A1 (en) 2021-03-04
ES2900825T3 (en) 2022-03-18
US10869869B2 (en) 2020-12-22
JP6684941B2 (en) 2020-04-22
JP2019142899A (en) 2019-08-29
KR20150047619A (en) 2015-05-04
CY1124812T1 (en) 2022-11-25
LT2892535T (en) 2021-12-10
RU2015105821A (en) 2016-10-20
HUE056646T2 (en) 2022-02-28
EP3981408A1 (en) 2022-04-13
HK1206642A1 (en) 2016-01-15
CN107308164A (en) 2017-11-03
RU2640180C2 (en) 2017-12-26
US20200054641A1 (en) 2020-02-20
EP2892535B1 (en) 2021-09-22
HRP20211817T1 (en) 2022-03-04
US20150216868A1 (en) 2015-08-06
CA2882437A1 (en) 2014-03-13
US20170202842A1 (en) 2017-07-20
US20180338979A1 (en) 2018-11-29
US20230330091A1 (en) 2023-10-19
JP2015527374A (en) 2015-09-17
SI2892535T1 (en) 2022-01-31
BR112015004578A2 (en) 2017-07-04
JP2018058859A (en) 2018-04-12
DK2892535T3 (en) 2022-01-03
PL2892535T3 (en) 2022-01-31
JP6511117B2 (en) 2019-05-15
WO2014039375A1 (en) 2014-03-13
CA2882437C (en) 2021-03-02
EP2892535A1 (en) 2015-07-15
PT2892535T (en) 2021-12-15
EP2892535A4 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
IN2015KN00449A (en)
MX2020004023A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX377157B (en) PREPARATION FOR USE IN THE TREATMENT OF GD2 POSITIVE CANCER.
MY188139A (en) Sodium channel modulators for the treatment of pain
MY170713A (en) Treatment protocol of diabetes type 2
MX373851B (en) METHODS OF ADMINISTRATION OF PIRFENIDONE TREATMENT.
MX365950B (en) Pyridazinone compounds and methods for the treatment of cystic fibrosis.
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
NZ603319A (en) Diabetes therapy
PH12015500954B1 (en) Device for extracorporeal blood treatment
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
PH12012501719A1 (en) Compounds for immunoproteasome inhibition
MX2014005928A (en) Heterocyclic inhibitors of glutaminase.
EA033067B1 (en) Method for treating metabolic disorders in a patient having a contraindication for a biguanide compound
PH12016502355A1 (en) Pharmaceutical composition
EP3141603A4 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
MX2013010050A (en) Proteasome inhibitor delanzomib for use in the treatment of lupus.
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
PH12014502065A1 (en) Vesicular formulations
MX2015008454A (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders.
MX2021014120A (en) Treatment of androgen deprivation therapy associated symptoms.
MX2018011607A (en) Sultiame for the treatment of sleep apnea.
TN2013000336A1 (en) 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.
GEP20196947B (en) Bremelanotide therapy for female sexual dysfunction